Revvity Inc vs Snowflake Inc — how do they compare? Revvity Inc trades at $154.64 (market cap $16.98B), while Snowflake Inc trades at $367.3 (market cap $121.15B). The key difference: Snowflake Inc is far larger — about 7.1× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Snowflake Inc for 54 Days on average.
| RVTY | SNOW | |
|---|---|---|
Market Cap | $16.98B | $121.15B |
Volume | 1,456,900 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $157.36 | $356.47 |
52-Week Low | $82.26 | $121.11 |
Typical Hold Time | 12 Days | 54 Days |
Enterprise Value | $19.30B | $121.57B |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Snowflake (SNOW) trades at $360.12, up 8.19% in the past 24 hours, with strong technical momentum and bullish moving average signals. The company continues to show impressive revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a net loss of $1.29 billion. Recent developments include a $3.75 billion convertible note offering and expanded partnerships with UiPath, while analysts maintain strong buy sentiment with an $418.03 consensus price target.
Snowflake presents a growth investment opportunity with accelerating revenue expansion and positive earnings beats, but faces significant execution risk due to persistent losses and high valuation multiples. The stock's 81% analyst buy rating reflects confidence in the company's AI data cloud positioning, though investors must weigh the premium valuation against ongoing profitability challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →